SEARCH:   Advanced

Blood, 15 March 2008, Vol. 111, No. 6, pp. 2984-2990. Prepublished online as a Blood First Edition Paper on January 8, 2008; DOI 10.1182/blood-2007-09-114082. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2007-09-114082v1 111/6/2984    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Davies, S. M. Articles by Relling, M. V. Search for Related Content PubMed PubMed Citation Articles by Davies, S. M. Articles by Relling, M. V. Related Collections Free Research Articles Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group Stella M. Davies1, Michael J. Borowitz2, Gary L. Rosner3, Kristin Ritz3, Meenakshi Devidas4, Naomi Winick5, Paul L. Martin6, Paul Bowman7, James Elliott1, Cheryl Willman8, Soma Das9, Edwin H. Cook9, and Mary V. Relling10 1 Department of Pediatrics, Cincinnati Children's Hospital and Medical Center, OH; 2 Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD; 3 Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, Houston; 4 Statistics, Children's Oncology Group and University of Florida, Gainesville; 5 Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX; 6 Department of Pediatrics, Duke University Medical Center, Durham, NC; 7 Department of Pediatrics, Cook Children's Medical Center, Fort Worth, TX; 8 Department of Pathology, New Mexico Cancer Center, Albuquerque; 9 Department of Psychiatry, Human Genetics and Medicine, University of Illinois in Chicago; and 10 Pharmaceutical Department, St Jude Children's Research Hospital, Memphis, TN Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy. Within known prognostic categories, the determinants of MRD are not known. We measured MRD by flow cytometry at day 8 (in blood) and at day 28 (in bone marrow) of induction therapy in more than 1000 children enrolled in Pediatric Oncology Group therapy protocols 9904, 9905, and 9906. We classified patients as "best risk" if they had cleared MRD by day 8 of therapy and as "worst risk" if they had MRD remaining in bone marrow at day 28, and tested whether MRD was related to polymorphisms in 16 loci in genes hypothesized to influence response to therapy in acute lymphoblastic leukemia (ALL). After adjusting for known prognostic features such as presence of the TEL-AML1 rearrangement, National Cancer Institute (NCI) risk status, ploidy, and race, the G allele of a common polymorphism in chemokine receptor 5 (CCR5) was associated with more favorable MRD status than the A allele (P = .009, logistic regression), when comparing "best" and "worst" risk groups. These data are consistent with growing evidence that both acquired and host genetics influence response to cancer therapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. Bassan, O. Spinelli, E. Oldani, T. Intermesoli, M. Tosi, B. Peruta, G. Rossi, E. Borlenghi, E. M. Pogliani, E. Terruzzi, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) Blood, April 30, 2009; 113(18): 4153 - 4162. [Abstract] [Full Text] [PDF] J. J. Yang, C. Cheng, W. Yang, D. Pei, X. Cao, Y. Fan, S. B. Pounds, G. Neale, L. R. Trevino, D. French, et al. Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia JAMA, January 28, 2009; 301(4): 393 - 403. [Abstract] [Full Text] [PDF] D. Campana Molecular Determinants of Treatment Response in Acute Lymphoblastic Leukemia Hematology, January 1, 2008; 2008(1): 366 - 373. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020